Wayland Group Corp MRRCF

***Financials***Growth Opportunity

[patels96]

People here only seem to think about the Short Term and completely ignore the Medium/Long Term. Furthermore, they blame management for the lack of direction, which is not fair because they did say in the financials "Limited Operating Financials".

I think 2017 was a strategic year for Maricann, remember that the fair value charge in convertible dentures/warrants was accounted for in Q2 of 2017. Given that approx. $37 Mil of the charge happened in Q2 2017 the effective increase in expenses from Q2 to Q4 was about $10 Mil. The additional $10 Mil increase was attributed to marketing initiatives, bringing on-board additional experience/expertise, pharmacy distribution agreements and optimizing production facilities. Considering the above, Maricann was going to end 2017 with a large loss per share, but management increased expenses marginally to position Maricann more competitively and set Maricann up for a great FYE 2018 onwards.

I believe that in 2-3 Years as the supply of cannabis increases the industry model will move from patient acquisition to wholesale model, which means that companies will have to sell cannabis for around $5 per gram. Given that Maricann is focused on the higher quality medical cannabis segment, as well as their initiative to reduce costs to become one of the lowest cost producer, this will allow them to preserve margins more effectively then the faster growing LPs such as ACB (which has been diluting shareholders like crazy)

Maricann (contrary to the article) has more the cash needed to fund Phase II and III of their expansion strategy. With only 133 Mil shares outstanding (182 Mil fully diluted), I think Maricann is well positioned for 2018, and I wont be surprised if they are able to $30-$40 Mil on revenues (significant growth). In addition, VESIsorb will definately allow Maricann to roll out more differentiated product lines compared to its competitors, which will allow for signifcant asset growth

So instead of focusing on the Short Term, try thinking about 2018 as a whole and going forward. I think Maricann at $1.60 is trading at a remarkable discount, and I wont be surprised if Maricann ends 2018 with a stock price between $4-$5, which tremendous growth going forward. Don't let these idiots get into your head, let the company do the talking

Best,
Maricann Shareholder